Business Wire | Nov 12, 2020 10:47AM EST

Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

Nov. 12, 2020

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 12, 2020--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin(r) (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).

The Quelicin(r) brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*.

Dr. Reddy's Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), is available in multi-dose vials.

Please see full prescribing information including boxed warning. https://www.drreddys.com/pi/succinylcholine-chloride.pdf

WARNING

RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS

There have been rare reports of acute rhabdomyolysis with hyperkalemia followedby ventricular dysrhythmias, cardiac arrest and death after the administrationof succinylcholine to apparently healthy pediatric patients who weresubsequently found to have undiagnosed skeletal muscle myopathy, mostfrequently Duchenne's muscular dystrophy.



This syndrome often presents as peaked T-waves and sudden cardiac arrest withinminutes after the administration of the drug in healthy appearing pediatricpatients (usually, but not exclusively, males, and most frequently 8 years ofage or younger). There have also been reports in adolescents.



Therefore, when a healthy appearing infant or child develops cardiac arrestsoon after administration of succinylcholine, not felt to be due to inadequateventilation, oxygenation or anesthetic overdose, immediate treatment forhyperkalemia should be instituted. This should include administration ofintravenous calcium, bicarbonate, and glucose with insulin, withhyperventilation. Due to the abrupt onset of this syndrome, routineresuscitative measures are likely to be unsuccessful. However, extraordinaryand prolonged resuscitative efforts have resulted in successful resuscitationin some reported cases. In addition, in the presence of signs of malignanthyperthermia, appropriate treatment should be instituted concurrently.



Since there may be no signs or symptoms to alert the practitioner to whichpatients are at risk, it is recommended that the use of succinylcholine inpediatric patients should be reserved for emergency intubation or instanceswhere immediate securing of the airway is necessary, e.g., laryngospasm,difficult airway, full stomach, or for intramuscular use when a suitable veinis inaccessible (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION).

Quelicin(r) is a trademark of Hospira, Inc

*IQVIA Retail and Non-Retail MAT September 2020

RDY-0820-308

About Dr. Reddy's Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues,and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005793/en/

CONTACT: INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH: +91-40-49002135)

CONTACT: MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com (PH: +91-40- 49002446)